These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25463037)

  • 1. Cancer drug development in China: recent advances and future challenges.
    Wu YL; Zhang H; Yang Y
    Drug Discov Today; 2015 Jun; 20(6):766-71. PubMed ID: 25463037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).
    Liu X; Belani CP
    Curr Mol Pharmacol; 2016; 9(3):182. PubMed ID: 26177639
    [No Abstract]   [Full Text] [Related]  

  • 3. The RACE to accelerate drug development for children with cancer.
    Pearson ADJ; Karres D; Reaman G; DuBois SG; Knox L; Scobie N; Vassal G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):714-716. PubMed ID: 32822672
    [No Abstract]   [Full Text] [Related]  

  • 4. Translational research in oncology--10 years of progress and future prospects.
    Doroshow JH; Kummar S
    Nat Rev Clin Oncol; 2014 Nov; 11(11):649-62. PubMed ID: 25286976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in Breast Cancer 2017-2018: New Drugs, New Drug Classes-and the Prospect of More to Come.
    Kaklamani VG
    Oncology (Williston Park); 2017 Dec; 31(12 Suppl 1):6-7. PubMed ID: 29299885
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
    Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
    Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and Opportunities With Oncology Drug Development in China.
    Bajaj G; Gupta M; Wang HH; Barrett JS; Tan M; Rupalla K; Bertz R; Sheng J
    Clin Pharmacol Ther; 2019 Feb; 105(2):363-375. PubMed ID: 29328503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Modern anti-cancer therapy: current state and future developments].
    Bokemeyer C; Hiddemann W
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2067. PubMed ID: 25268204
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer Research UK Centre for Drug Development: translating 21st-century science into the cancer medicines of tomorrow.
    Ritchie JW; Williams RJ
    Drug Discov Today; 2015 Aug; 20(8):995-1003. PubMed ID: 25794601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision Oncology: The Road Ahead.
    Senft D; Leiserson MDM; Ruppin E; Ronai ZA
    Trends Mol Med; 2017 Oct; 23(10):874-898. PubMed ID: 28887051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-polymer hybrid nanocarrier-mediated cancer therapeutics: current status and future directions.
    Garg NK; Tandel N; Jadon RS; Tyagi RK; Katare OP
    Drug Discov Today; 2018 Sep; 23(9):1610-1621. PubMed ID: 29857164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
    Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
    Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    Christenson ES; Jaffee E; Azad NS
    Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing Drugs in Oncology: Next Steps.
    Verbaanderd C; Meheus L; Huys I; Pantziarka P
    Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathology in therapeutics: where are we now, and where are we going?
    Harrison DJ; Faratian D
    Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic additions and possible deletions in oncology in 2011.
    Holstein SA; Hohl RJ
    Clin Pharmacol Ther; 2012 Jan; 91(1):15-7. PubMed ID: 22179625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. There is no better time than the present: nanotechnology as a disruptive innovation for drug development.
    Oo C; Tsai JC; Kao HD
    Drug Discov Today; 2015 Jun; 20(6):645-7. PubMed ID: 25835226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.